DE60233434D1 - Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie - Google Patents

Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie

Info

Publication number
DE60233434D1
DE60233434D1 DE60233434T DE60233434T DE60233434D1 DE 60233434 D1 DE60233434 D1 DE 60233434D1 DE 60233434 T DE60233434 T DE 60233434T DE 60233434 T DE60233434 T DE 60233434T DE 60233434 D1 DE60233434 D1 DE 60233434D1
Authority
DE
Germany
Prior art keywords
amino acids
units
amino
oligopeptides
methacryloylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60233434T
Other languages
German (de)
English (en)
Inventor
Karel Ulbrich
Tomas Etrych
Blanka Rihova
Marketa Jelinkova
Marek Kovar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Application granted granted Critical
Publication of DE60233434D1 publication Critical patent/DE60233434D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60233434T 2001-12-20 2002-12-20 Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie Expired - Lifetime DE60233434D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20014653A CZ293787B6 (cs) 2001-12-20 2001-12-20 pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii
PCT/CZ2002/000070 WO2003053473A2 (en) 2001-12-20 2002-12-20 Ph-sensitive polymeric conjugates of an anthracycline drug

Publications (1)

Publication Number Publication Date
DE60233434D1 true DE60233434D1 (de) 2009-10-01

Family

ID=5473644

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60233434T Expired - Lifetime DE60233434D1 (de) 2001-12-20 2002-12-20 Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie

Country Status (18)

Country Link
US (1) US7919076B2 (OSRAM)
EP (2) EP1782833A3 (OSRAM)
JP (1) JP4718117B2 (OSRAM)
KR (1) KR20040076874A (OSRAM)
AT (1) ATE439864T1 (OSRAM)
AU (1) AU2002366715A1 (OSRAM)
CA (1) CA2470976A1 (OSRAM)
CZ (1) CZ293787B6 (OSRAM)
DE (1) DE60233434D1 (OSRAM)
DK (1) DK1463529T5 (OSRAM)
EA (1) EA007353B1 (OSRAM)
ES (1) ES2331303T3 (OSRAM)
HU (1) HUP0500541A3 (OSRAM)
PL (1) PL216518B1 (OSRAM)
PT (1) PT1463529E (OSRAM)
SI (1) SI1463529T1 (OSRAM)
SK (1) SK2912004A3 (OSRAM)
WO (1) WO2003053473A2 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ294996B6 (cs) * 2003-07-16 2005-04-13 Ústav Makromolekulární Chemie Av Čr Reaktivní polymery a kopolymery na bázi N-(2-hydroxypropyl)methakrylamidu, způsob jejich přípravy a jejich použití pro syntézu polymerních léčiv, pro modifikaci biologicky aktivních proteinů a přípravu systémů pro dopravu genů
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
CA2583700A1 (en) 2004-08-11 2006-02-23 Arqule, Inc. Quinone prodrug compositions and methods of use
CZ2005558A3 (cs) * 2005-09-05 2007-04-04 Zentiva, A. S. Zpusob prípravy polymerních konjugátu doxorubicinu s pH-rízeným uvolnováním léciva
CZ2006207A3 (cs) * 2006-03-28 2008-01-16 Zentiva, A. S. Micelární nosiče léčiv s protinádorovou aktivitou
EP2799868A3 (en) 2006-08-09 2015-04-22 Sumitomo Bakelite Co., Ltd. Sugar chain-capturing substance and use thereof
CZ2006505A3 (cs) * 2006-08-09 2008-04-09 Zentiva, A. S. Polymerní konjugáty doxorubicinu s pH-rízeným uvolnováním léciva a zpusob jejich prípravy
CZ298945B6 (cs) * 2006-09-18 2008-03-19 Zentiva, A. S. Polymerní lécivo a zpusob jeho výroby
US7790765B2 (en) 2007-04-30 2010-09-07 Arqule, Inc. Hydroxy sulfonate of quinone compounds and their uses
CZ301288B6 (cs) * 2008-10-23 2009-12-30 Zentiva, A. S Polymerní prípravek se synergickým úcinkem pri lécbe nádorových onemocnení
CZ302830B6 (cs) * 2009-12-15 2011-11-30 Ústav makromolekulární chemie AV CR, v.v.i. Vysokomolekulární polymerní nosice léciv odvozené od dendrimeru a jejich konjugáty s lécivy pro lécbu zejména pevných nádoru
EP3069715A1 (en) 2015-03-20 2016-09-21 Salmon Pharma GmbH Immediate release dosage forms of Atomoxetine
EP3525808A4 (en) * 2016-10-14 2020-06-24 University of Utah Research Foundation ANTIBODY-POLYMER-DRUG CONJUGATES
WO2020214858A1 (en) * 2019-04-17 2020-10-22 Avidea Technologies, Inc. Compositions and methods of manufacturing star polymers for ligand display and/or drug delivery
CZ309828B6 (cs) * 2019-10-09 2023-11-15 I.T.A.-Intertact S.R.O. Fluorescenční polymer, fluorescenční sonda a konjugační sada pro pokročilé funkční analýzy buněk v hematologii, imunologii a mikrobiologii, způsob jejich přípravy a jejich použití
EP4051320A1 (en) * 2019-10-30 2022-09-07 CIS Pharma AG Biocompatible polymeric drug carriers for delivering active agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs

Also Published As

Publication number Publication date
CZ293787B6 (cs) 2004-07-14
DK1463529T5 (da) 2011-06-27
WO2003053473A3 (en) 2004-04-29
HUP0500541A2 (hu) 2005-09-28
PT1463529E (pt) 2009-11-03
ATE439864T1 (de) 2009-09-15
ES2331303T3 (es) 2009-12-29
WO2003053473A2 (en) 2003-07-03
ES2331303T9 (es) 2011-08-18
CA2470976A1 (en) 2003-07-03
US7919076B2 (en) 2011-04-05
EP1463529A2 (en) 2004-10-06
AU2002366715A1 (en) 2003-07-09
EA200400802A1 (ru) 2005-02-24
CZ20014653A3 (cs) 2003-08-13
PL216518B1 (pl) 2014-04-30
EP1463529B9 (en) 2011-03-23
JP4718117B2 (ja) 2011-07-06
US20060057099A1 (en) 2006-03-16
EP1782833A3 (en) 2008-03-19
SI1463529T1 (sl) 2010-01-29
JP2005519044A (ja) 2005-06-30
PL370719A1 (en) 2005-05-30
HUP0500541A3 (en) 2011-08-29
EP1463529B1 (en) 2009-08-19
AU2002366715A8 (en) 2003-07-09
SK2912004A3 (en) 2004-12-01
EP1782833A2 (en) 2007-05-09
KR20040076874A (ko) 2004-09-03
DK1463529T3 (da) 2009-10-19
EA007353B1 (ru) 2006-10-27

Similar Documents

Publication Publication Date Title
ATE439864T1 (de) Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie
CN120248019B (zh) 生物活性物偶联物及其制备方法和用途
US7893023B2 (en) Prodrugs activated by plasmin and their use in cancer chemotherapy
RU2010119521A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
CY1117065T1 (el) Υβριδικη και διαδοχικη εκφραση νεϊσσεριακα λαμβανομενων πρωτεϊνων
BR0013577A (pt) Efetores de dipeptidil peptidase iv para uso tópico
TR200200252T2 (tr) Şimerik polipeptidler, bunların üretimi için yöntem ve kullanımı
PA8497801A1 (es) Conjugados de eritropoyetina
RU2009132006A (ru) Антитела и содержащие их фармацевтические композиции, подходящие для ингибирования активности металлопротеинов
ATE437647T1 (de) Transporter mit beabstandeten arginin-teilchen
JP2005519044A5 (OSRAM)
DK1179537T3 (da) Fastfasepeptidsyntesefremgangsmåde
CA2657476C (en) Protein-binding methotrexate derivatives and medicaments containing the same
CN1056084C (zh) 抗与表面抗原相关的cd33的免疫毒素
ES8103026A1 (es) Un procedimiento para la preparacion de un peptido
Philpott et al. Improved selective cytotoxicity with an antibody-diphtheria toxin conjugate
Pechar et al. Conjugates of Antibody‐Targeted PEG Multiblock Polymers with Doxorubicin in Cancer Therapy
Miklán et al. Cell-penetrating and targeting peptide conjugates of antitumor drugs: Synthesis, chemical and in vitro biological characterization
Woo et al. Ricin A immunotoxins of IgG and Fab of anti-CALLA monoclonal antibody: Effect of water soluble long-chain SPDP on conjugate yield, immunoselectivity and cytotoxicity
Říhová et al. Targetable photoactivatable drugs
Hiebert et al. Synthesis of fluorescent muramyl dipeptide congeners. 2
KOJIMA et al. Metastasis by Synthetic Polymer Containing RGDS Peptide
Watson Development of Amphipathic Beta-Strand Mimics as Potential Membrane Active Antibiotics

Legal Events

Date Code Title Description
8364 No opposition during term of opposition